Efficacy and safety of ingenol mebutate 0.015% gel after cryosurgery of actinic keratosis: 12-month results

Journal of Drugs in Dermatology

Volumn 13, Issue 6, 2014, Pages 741-747

  Berman, Brian ^a   Goldenberg, Gary ^b   Hanke, C William ^c   Tyring, Stephen K ^d   Werschler, Wm Philip ^e   Knudsen, Kim Mark ^f   Larsson, Thomas ^f   Swanson, Neil ^g  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c Laser and Skin Surgery Center of Indiana   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f LEO PHARMA A S   (Denmark)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INGENOL MEBUTATE; 3-INGENYL ANGELATE; DERMATOLOGICAL AGENT; DITERPENE; GEL;

ACTINIC KERATOSIS; ADULT; AGED; APPLICATION SITE DISCOLORATION; APPLICATION SITE INDURATION; APPLICATION SITE PAIN; APPLICATION SITE PRURITUS; APPLICATION SITE REACTION; ARTICLE; CONTROLLED STUDY; CRYOSURGERY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GEL; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SKIN TIGHTNESS; SKIN TOXICITY; TREATMENT RESPONSE; CLINICAL TRIAL; FOLLOW UP; KERATOSIS, ACTINIC; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; CRYOSURGERY; DERMATOLOGIC AGENTS; DITERPENES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GELS; HUMANS; KERATOSIS, ACTINIC; MALE; MIDDLE AGED;

EID: 84903377481     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Einspahr JG, Bowden GT, Alberts DS. Skin cancer chemoprevention: strategies to save our skin. Recent Results Cancer Res. 2003;163:151-164.
2. Babilas P, Landthaler M, Szeimies RM. [Actinic keratoses]. Hautarzt. 2003;54:551-560.
3. Memon AA, Tomenson JA, Bothwell J, et al. Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol. 2000;142:1154-1159. (Pubitemid 30418302)
4. Rosen T, Lebwohl MG. Prevalence and awareness of actinic keratosis: barriers and opportunities. J Am Acad Dermatol. 2013;68:S2-S9.
5. Rigel DS, Stein Gold LF. The importance of early diagnosis and treatment of actinic keratosis. J Am Acad Dermatol. 2013;68(Suppl 1):S20-S27.
6. Schaefer I, Augustin M, Spehr C, et al. Prevalence and risk factors of actinic keratoses in Germany - analysis of multisource data. J Eur Acad Dermatol Venereol. 2014;28:309-313.
7. Berger DS, Urbach F. A climatology of sunburning ultraviolet radiation. Photochem Photobiol. 1982;35:187-192.
8. Nestor MS, Zarraga MB. The incidence of nonmelanoma skin cancers and actinic keratoses in South Florida. J Clin Aesthet Dermatol. 2012;5:20-24.
9. Ceilley RI, Jorizzo JL. Current issues in the management of actinic keratosis. J Am Acad Dermatol. 2013;68(Suppl 1):S28-S38.
10. Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol. 2000;42:23-24.
11. Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet. 1988;1:795-797. (Pubitemid 18094914)
12. Tran DT, Salmon R. Field treatment of facial and scalp actinic keratoses with photodynamic therapy: survey of patient perceptions of treatment satisfaction and outcomes. Australas J Dermatol. 2011;52:195-201.
13. Balkrishnan R, Cayce KA, Kulkarni AS, et al. Predictors of treatment choices and associated outcomes in actinic keratoses: results from a national physician survey study. J Dermatolog Treat. 2006;17:162-166. (Pubitemid 44147835)
14. Dinehart SM. The treatment of actinic keratoses. J Am Acad Dermatol. 2000;42:25-28.
15. Halpern AC, Hanson LJ. Awareness of, knowledge of and attitudes to nonmelanoma skin cancer (NMSC) and actinic keratosis (AK) among physicians. Int J Dermatol. 2004;43:638-642. (Pubitemid 39276288)
16. Krawtchenko N, Roewert-Huber J, Ulrich M, et al. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol. 2007;157(Suppl 2):34-40. (Pubitemid 350179628)
17. Stockfleth E. The paradigm shift in treating actinic keratosis: a comprehensive strategy. J Drugs Dermatol. 2012;11:1462-1467.
18. LEO Pharma. Picato® (ingenol mebutate) gel, 0.015%, 0.05%. Prescribing information. Available at: www.picato.com/-pdf/ PrescribingInformation.pdf. Accessed February 6, 2014.
19. Berman B. New developments in the treatment of actinic keratosis: focus on ingenol mebutate gel. Clin Cosmet Investig Dermatol. 2012;5:111-122.
20. Keating GM. Ingenol mebutate gel 0.015% and 0.05%: in actinic keratosis. Drugs. 2012;72:2397-2405.
21. Ogbourne SM, Suhrbier A, Jones B, et al. Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death. Cancer Res. 2004;64:2833-2839. (Pubitemid 38500622)
22. Stahlhut M, Bertelsen M, Hoyer-Hansen M, et al. Ingenol mebutate: induced cell death patterns in normal and cancer epithelial cells. J Drugs Dermatol. 2012;11:1181-1192.
23. Hampson P, Kavanagh D, Smith E, et al. The anti-tumor agent, ingenol-3-angelate (PEP005), promotes the recruitment of cytotoxic neutrophils by activation of vascular endothelial cells in a PKC-delta dependent manner. Cancer Immunol Immunother. 2008;57:1241-1251.
24. Rosen RH, Gupta AK, Tyring SK. Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response. J Am Acad Dermatol. 2012;66:486-493.
25. Lebwohl M, Swanson N, Anderson LL, et al. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012;366:1010-1019.
26. Lebwohl M, Shumack S, Gold LS, et al. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol. 2013;149:666-670.
27. Berman B, Goldenberg G, Hanke CW, et al. Efficacy and safety of ingenol mebutate 0.015% gel 3 weeks after cryosurgery of actinic keratosis: 11-week results. J Drugs Dermatol. 2014;13:154-160.
28. TNS ICAP Healthcare. A Report on the Actinic Keratosis Market Landscape in Australia. Athens: TNS ICAP Healthcare. 2008.
29. TNS ICAP Healthcare. A Study of Australians With Actinic Keratosis. Athens: TNS ICAP Healthcare. 2008.
30. Thai KE, Fergin P, Freeman M, et al. A prospective study of the use of cryosurgery for the treatment of actinic keratoses. Int J Dermatol. 2004;43:687-692. (Pubitemid 39276301)
31. Berlin JM, Rigel DS. Diclofenac sodium 3% gel in the treatment of actinic keratoses postcryosurgery. J Drugs Dermatol. 2008;7:669-673.
32. Jorizzo J, Weiss J, Vamvakias G. One-week treatment with 0.5% fluorouracil cream prior to cryosurgery in patients with actinic keratoses: a double-blind, vehicle-controlled, long-term study. J Drugs Dermatol. 2006;5:133-139.
33. Tan JK, Thomas DR, Poulin Y, et al. Efficacy of imiquimod as an adjunct to cryotherapy for actinic keratoses. J Cutan Med Surg. 2007;11:195-201.
34. Jorizzo JL, Markowitz O, Lebwohl MG, et al. A randomized, double-blinded, placebo-controlled, multicenter, efficacy and safety study of 3.75% imiquimod cream following cryosurgery for the treatment of actinic keratoses. J Drugs Dermatol. 2010;9:1101-1108.
35. Serra-Guillen C, Nagore E, Hueso L, et al. A randomized pilot comparative study of topical methyl aminolevulinate photodynamic therapy versus imiquimod 5% versus sequential application of both therapies in immunocompetent patients with actinic keratosis: clinical and histologic outcomes. J Am Acad Dermatol. 2012;66:e131-e137.